Skip to content
Abierto

Presolicitation

Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

NIH-26-006363-IntentNotice

Office of the Assistant Secretary for Administration (Asa), Program Support Center Acq MGMT SVC. In-Vitro Diagnostic Substance Manufacturing.

Response deadline

February 14, 2026 at 1:00 PM EST

Closed 215 days ago. Posted January 30, 2026, first published January 30, 2026. Scheduled to archive March 1, 2026.

Description

As published on SAM.gov.

This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.

The intent is to award a contract on a solesource basis instead of competititon for Nucleic acid–based reagents for in vivo transient protein expression forthe National Cancer Institute and Center for Cancer Research. The supplies required are nucleic acid-based reagents. The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models.

The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models. Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models.

Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies.

These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. January 30, 2026

    Presolicitation

    Due February 14, 2026 at 1:00 PM EST. SAM.gov, notice 16f0d3a0ac4244809319904e2656f3c7

  2. January 30, 2026

    Presolicitation

    Due February 14, 2026 at 1:00 PM EST. SAM.gov, notice e3675be32c5f47f3801816ac68017a33

Points of contact